Advances in clinical applications of tissue proteomics: Opportunities and challenges

Expert Review of Proteomics

Volumn 11, Issue 5, 2014, Pages 531-533

  Dogan, Ahmet ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

amyloidosis; cancer; immunoglobulin; mass spectrometry; proteomics; transthyretin

Indexed keywords

AMYLOIDOSIS; CANCER TISSUE; CLINICAL LABORATORY; CLINICAL PRACTICE; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEOMICS; REVIEW; MEDICAL RESEARCH; METABOLISM; NEOPLASMS; PROCEDURES; TRENDS;

PROTEOME;

AMYLOIDOSIS; BIOMEDICAL RESEARCH; HUMANS; MASS SPECTROMETRY; NEOPLASMS; PROTEOME; PROTEOMICS;

EID: 84907261301     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2014.953062     Document Type: Review

References (18)

1. Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009;27(7): 633-41
2. Ellis MJ, Gillette M, Carr SA, et al. Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Cancer Discov 2013;3(10):1108-12
3. Whiteaker JR, Halusa GN, Hoofnagle AN, et al. CPTAC Assay Portal: A repository of targeted proteomic assays. Nat Methods 2014;11(7):703-4
4. Zhang B, Wang J, Wang X, et al. Proteogenomic characterization of human colon and rectal cancer. Nature 2014. [Epub ahead of print]
5. Casadonte R, Caprioli RM. Proteomic analysis of formalin-fixed paraffin-embedded tissue by MALDI imaging mass spectrometry. Nat Protoc 2011;6(11): 1695-709
6. Wisniewski JR, Dus K, Mann M. Proteomic workflow for analysis of archival formalin-fixed and paraffin-embedded clinical samples to a depth of 10000 proteins. Proteomics Clin Appl 2013; 7(3-4):225-33
7. Hembrough T, Thyparambil S, Liao WL, et al. Selected reaction monitoring (SRM) analysis of epidermal growth factor receptor (EGFR) in formalin fixed tumor tissue. Clin Proteomics 2012;9(1):5
8. Hembrough T, Thyparambil S, Liao WL, et al. Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. J Mol Diagn 2013;15(4):454-65
9. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011; 29(14):1924-33
10. Theis JD, Dasari S, Vrana JA, et al. Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis. J Mass Spectrom 2013;48(10): 1067-77
11. Vrana JA, Theis JD, Gamez JD, et al. Diagnosis and typing of cardiac amyloidosis in routine clinical specimens by mass spectrometry based proteomic analysis. Laboratory Investig 2009;89:80a-A
12. Vrana JA, Theis JD, Dasari S, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica 2014;99(7):1239-47
13. Dasari S, Theis JD, Vrana JA, et al. Clinical proteome informatics workbench detects pathogenic mutations in hereditary amyloidoses. J Proteome Res 2014. [Epub ahead of print]
14. Rowczenio D, Dogan A, Theis JD, et al. Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol 2011; 179(4):1978-87
15. D'Souza A, Theis JD, Vrana JA, Dogan A. Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration. Amyloid 2014;21(2):71-5
16. Valleix S, Gillmore JD, Bridoux F, et al. Hereditary systemic amyloidosis due to Asp76Asn variant beta2-microglobulin. N Engl J Med 2012;366(24):2276-83
17. Said SM, Sethi S, Valeri AM, et al. Characterization and outcomes of renal leukocyte chemotactic factor 2-Associated amyloidosis. Kidney Int 2014;86(2):370-7
18. Mereuta OM, Theis JD, Vrana JA, et al. Leukocyte cell-derived chemotaxin 2 (LECT2)-Associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood 2014;123(10):1479-82.